Pharmacogenetic Data System for Adverse Drug Reaction Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current systems lack effective business models to support the computerized implementation and reimbursement of medical and genetic data systems for predicting and preventing adverse drug reactions, particularly in providing relevant information at the point of care and managing costs.
Innovation Solution
A digital, computer-implemented system with predictive algorithms and graphical user interfaces that process metabolomic and pharmacogenetic data to issue warnings on potential drug interactions, integrated with a business model for automated reimbursement and data access, enabling real-time decision-making and cost management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If computerized systems and databases are implemented to store and process metabolic and pharmacogenetic data, then the ability to interpret data and provide personalized drug interaction warnings is improved, but the cost of software development, database maintenance, and infrastructure increases
Solution Approach 1:
The system performs multiple functions including data storage, predictive algorithm processing, graphical user interface display, and automated reimbursement management within a single integrated platform, reducing the need for separate systems and lowering overall software development and maintenance costs
Solution Approach 2:
The system includes automated reimbursement management capabilities that handle billing and reimbursement processes without requiring manual intervention, reducing operational costs and infrastructure requirements while maintaining high data interpretation accuracy
2Loss of time
If extensive software development is performed to display and prioritize relevant information at the point of care, then the relevance and timeliness of drug interaction warnings is improved, but the complexity of the system increases
Solution Approach 1:
The system pre-processes and stores metabolic and pharmacogenetic data in structured databases before clinical use, and pre-runs predictive algorithms to identify potential drug interactions, so that when a clinician queries the system at the point of care, results are immediately available without complex real-time processing
Solution Approach 2:
The graphical user interface acts as an intermediary layer that simplifies complex database queries and algorithm outputs into user-friendly drug interaction warnings and recommendations, reducing the perceived software complexity for end users while maintaining fast information delivery
3Duration of action of stationary object
If integrated reimbursement tools are implemented to cover equipment and database costs, then the sustainability of the system is improved, but the business model complexity increases
Solution Approach 1:
The system merges clinical functionality with reimbursement management in a single integrated platform, combining drug interaction prediction tools with automated billing and reimbursement processing, thereby simplifying the business model by eliminating the need for separate reimbursement systems and reducing overall operational complexity
Data Source
AI summary
A computerized tool and method for delivery of pharmacogenetic and pharmacological information, comprising a core system having algorithms and databases for storing, collating, accessing, cross-referencing, and interpreting genetic and pharmacologic data, with a graphical user interface for a client network of providers of laboratory genetic testing services to access the core services under contract. The system includes “paypoints” in support of improved business models. Included are mechanisms for ‘pass through’ third party and insurance reimbursement for interpretive reports, insurance reimbursement for on-line access to pharmacogenetic information at the point of care, tools for market segmentation, and a conversion tool for capturing new subscribers. Also disclosed are tools and predictive algorithms for preventing drug-drug and drug-gene adverse drug reactions.